T1	CHEM 126 133	BIIB074
#1	AnnotatorNotes T1	C4505505; BIIB074; Amino Acid, Peptide, or Protein · Biologically Active Substance
T2	PROC 57 109	evaluar a largo plazo la seguridad, la tolerabilidad
T3	DISO 149 166	dolor neuropático
#2	AnnotatorNotes T3	C0027796; Neuralgia; Sign or Symptom
T4	DISO 171 195	radiculopatía lumbosacra
#3	AnnotatorNotes T4	C0154738; Lumbosacral radiculopathy; Disease or Syndrome
T5	ANAT 185 195	lumbosacra
#4	AnnotatorNotes T5	C0024094; Lumbosacral Region; Body Location or Region
T6	PROC 217 262	Estudio de ampliación abierto y no controlado
T7	PROC 268 306	evaluar la seguridad, la tolerabilidad
T8	DISO 378 395	dolor neuropático
#5	AnnotatorNotes T8	C0027796; Neuralgia; Sign or Symptom
T9	DISO 400 424	radiculopatía lumbosacra
#6	AnnotatorNotes T9	C0154738; Lumbosacral radiculopathy; Disease or Syndrome
T10	ANAT 414 424	lumbosacra
#7	AnnotatorNotes T10	C0024094; Lumbosacral Region; Body Location or Region
T11	DISO 447 464	Dolor neuropático
#8	AnnotatorNotes T11	C0027796; Neuralgia; Sign or Symptom
T12	DISO 469 493	radiculopatía lumbosacra
#9	AnnotatorNotes T12	C0154738; Lumbosacral radiculopathy; Disease or Syndrome
T13	ANAT 483 493	lumbosacra
#10	AnnotatorNotes T13	C0024094; Lumbosacral Region; Body Location or Region
T14	CHEM 341 348	BIIB074
#11	AnnotatorNotes T14	C4505505; BIIB074; Amino Acid, Peptide, or Protein · Biologically Active Substance
T15	PROC 748 784	consentimiento informado por escrito
#12	AnnotatorNotes T15	C0811741; Obtain informed written consent; Health Care Activity
T16	PROC 989 998	protocolo
#13	AnnotatorNotes T16	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T17	PROC 1095 1135	interrumpan el tratamiento a doble ciego
T18	PROC 1172 1181	protocolo
#14	AnnotatorNotes T18	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T19	DISO 1292 1313	problema de seguridad
T20	PROC 1540 1549	protocolo
#15	AnnotatorNotes T20	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T21	PROC 1604 1651	ensayo clínico de fase IIb y diseño doble ciego
T22	DISO 1677 1679	AA
#16	AnnotatorNotes T22	C0877248; Adverse event; Pathologic Function
T23	PROC 1705 1716	tratamiento
#17	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	PROC 1754 1780	se continúa el tratamiento
#18	AnnotatorNotes T24	C2091305; continue current medication; Therapeutic or Preventive Procedure
T25	PROC 1795 1823	interrupción del tratamiento
#19	AnnotatorNotes T25	C0850893; stop medication; Therapeutic or Preventive Procedure
T26	DISO 1916 1919	AAG
#20	AnnotatorNotes T26	C1519255; Serious Adverse Event; Finding
T27	PROC 1841 1873	ensayo a doble ciego de fase IIb
T28	DISO 1911 1913	AA
#21	AnnotatorNotes T28	C0877248; Adverse event; Pathologic Function
T29	PROC 1965 1974	protocolo
#22	AnnotatorNotes T29	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T30	PROC 2038 2064	interrumpir el tratamiento
T31	PROC 2071 2120	fase a doble ciego del ensayo clínico de fase IIb
T32	DISO 1264 1269	dolor
#23	AnnotatorNotes T32	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T33	DISO 1682 1685	AAG
#24	AnnotatorNotes T33	C1519255; Serious Adverse Event; Finding
T34	CHEM 1785 1792	BIIB074
#25	AnnotatorNotes T34	C4505505; BIIB074; Amino Acid, Peptide, or Protein · Biologically Active Substance
T35	Date 12 16	2015
T36	Date 65 78	a largo plazo
T37	LIVB 137 144	sujetos
#26	AnnotatorNotes T37	C0681850; Study Subject; Group
T39	Date 349 362	a largo plazo
T40	LIVB 366 373	sujetos
#27	AnnotatorNotes T40	C0681850; Study Subject; Group
T41	LIVB 524 533	pacientes
#28	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	PHYS 676 687	Comprensión
#29	AnnotatorNotes T42	C0162340; Comprehension; Mental Process
T44	Date 1030 1042	la semana 14
T45	Date 1044 1050	día 99
T46	LIVB 1083 1090	sujetos
#30	AnnotatorNotes T46	C0681850; Study Subject; Group
T47	Date 1211 1223	la semana 14
T48	Date 1225 1231	día 99
T50	Neg_cue 1341 1343	No
T51	LIVB 1366 1375	pacientes
#31	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T55	Date 2004 2016	la semana 14
T56	Date 2018 2024	día 99
T57	Date 2226 2238	la semana 14
T58	Date 2240 2246	día 99
T59	LIVB 2315 2327	investigador
#32	AnnotatorNotes T59	C0035173; Research Personnel; Professional or Occupational Group
T60	LIVB 2398 2404	sujeto
#33	AnnotatorNotes T60	C0681850; Study Subject; Group
T38	PROC 611 624	reclutamiento
#34	AnnotatorNotes T38	C0242800; Patient Recruitment; Research Activity
T43	PROC 1458 1471	reclutamiento
#35	AnnotatorNotes T43	C0242800; Patient Recruitment; Research Activity
T49	PROC 1020 1026	visita
#36	AnnotatorNotes T49	C1512346; Patient Visit; Health Care Activity
T52	PROC 1201 1207	visita
#37	AnnotatorNotes T52	C1512346; Patient Visit; Health Care Activity
T53	PROC 1160 1167	visitas
#38	AnnotatorNotes T53	C1512346; Patient Visit; Health Care Activity
T54	PROC 1994 2000	visita
#39	AnnotatorNotes T54	C1512346; Patient Visit; Health Care Activity
T61	PROC 1953 1960	visitas
#40	AnnotatorNotes T61	C1512346; Patient Visit; Health Care Activity
T62	PROC 2216 2222	visita
#41	AnnotatorNotes T62	C1512346; Patient Visit; Health Care Activity
A2	Assertion T51 Negated
#42	AnnotatorNotes T36	C0443252; Long-term; Temporal Concept
#43	AnnotatorNotes T39	C0443252; Long-term; Temporal Concept
#44	AnnotatorNotes T7	C3274448; Tolerability Study; Research Activity + C1705187; Safety Study; Research Activity
#45	AnnotatorNotes T19	C2362502; Safety Issues; Injury or Poisoning 
#46	AnnotatorNotes T30	C0850893; stop medication; Therapeutic or Preventive Procedure
T63	Observation 1933 1960	acudido a todas las visitas
A1	Assertion T63 Negated
T64	Neg_cue 1924 1926	No
T65	Neg_cue 249 251	no
T66	Quantifier_or_Qualifier 252 262	controlado
A3	Assertion T66 Negated
R1	Negation Arg1:T65 Arg2:T66	
R2	Negation Arg1:T50 Arg2:T51	
T67	Observation 1380 1413	presenten alguno de los criterios
A4	Assertion T67 Negated
#47	AnnotatorNotes T67	C3481472; Exclusion criteria present; Finding (?)
R4	Negation Arg1:T50 Arg2:T67	
R5	Overlap Arg1:T67 Arg2:T43	
R6	Negation Arg1:T64 Arg2:T63	
T68	Observation 2380 2404	participación del sujeto
A5	Assertion T68 Contraindicated
#48	AnnotatorNotes T68	C1278516; Patient participation status; Finding
T69	Observation 2150 2177	participación en el estudio
A6	Assertion T69 Contraindicated
#49	AnnotatorNotes T69	C1278516; Patient participation status; Finding (?)
R7	Overlap Arg1:T2 Arg2:T36	
T70	Observation 115 121	efecto
#50	AnnotatorNotes T70	C1518681; Outcome of Therapy; Finding (?)
R8	Causes Arg1:T1 Arg2:T70	
T71	Observation 330 336	efecto
#51	AnnotatorNotes T71	C1518681; Outcome of Therapy; Finding (?)
R9	Causes Arg1:T14 Arg2:T71	
R10	Experiences Arg1:T37 Arg2:T70	
R11	Experiences Arg1:T37 Arg2:T1	
R12	Experiences Arg1:T37 Arg2:T3	
R13	Location_of Arg1:T5 Arg2:T4	
R14	Causes Arg1:T4 Arg2:T3	
R15	Experiences Arg1:T37 Arg2:T4	
R16	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T66	
R18	Overlap Arg1:T71 Arg2:T39	
R17	Experiences Arg1:T40 Arg2:T71	
R19	Experiences Arg1:T40 Arg2:T14	
R20	Experiences Arg1:T40 Arg2:T8	
R21	Experiences Arg1:T40 Arg2:T9	
R22	Location_of Arg1:T10 Arg2:T9	
R23	Causes Arg1:T9 Arg2:T8	
R24	Causes Arg1:T12 Arg2:T11	
R25	Location_of Arg1:T13 Arg2:T12	
T72	Observation 540 566	reunir todos los criterios
#52	AnnotatorNotes T72	C4329786; Eligibility Criteria Met By Subject; Finding
R26	Overlap Arg1:T72 Arg2:T38	
T73	Observation 710 717	riesgos
T74	CONC 692 700	objetivo
#53	AnnotatorNotes T74	C0018017; objective (goal); Intellectual Product 
T75	Observation 972 998	Finalización del protocolo
R27	Overlap Arg1:T75 Arg2:T49	
R28	Overlap Arg1:T49 Arg2:T44	
R29	Overlap Arg1:T49 Arg2:T45	
R30	Overlap Arg1:T75 Arg2:T44	
R31	Overlap Arg1:T75 Arg2:T45	
T76	Observation 1068 1078	participar
#54	AnnotatorNotes T76	C1278516; Patient participation status; Finding
R32	Experiences Arg1:T46 Arg2:T17	
T77	Observation 1141 1167	acudan a todas las visitas
R33	Overlap Arg1:T52 Arg2:T47	
R34	Overlap Arg1:T52 Arg2:T48	
T78	Observation 1236 1269	documenten su puntuación de dolor
R35	Experiences Arg1:T46 Arg2:T32	
R36	Overlap Arg1:T77 Arg2:T53	
R37	Overlap Arg1:T77 Arg2:T52	
R38	Experiences Arg1:T46 Arg2:T19	
T79	Observation 1519 1549	Desviación mayor del protocolo
#55	AnnotatorNotes T79	C0184543; Noncompliance with therapeutic regimen; Finding (?)
R3	Causes Arg1:T23 Arg2:T22	
R39	Causes Arg1:T23 Arg2:T33	
T80	Observation 1732 1750	aumento del riesgo
R40	Causes Arg1:T33 Arg2:T80	
R41	Causes Arg1:T22 Arg2:T80	
#56	AnnotatorNotes T80	C4699158; Increased risk; Finding
R42	Before Arg1:T24 Arg2:T80	
R43	Used_for Arg1:T34 Arg2:T24	
R44	Causes Arg1:T28 Arg2:T25	
R45	Causes Arg1:T26 Arg2:T25	
R46	Overlap Arg1:T63 Arg2:T54	
R47	Overlap Arg1:T63 Arg2:T61	
R48	Overlap Arg1:T54 Arg2:T55	
R49	Overlap Arg1:T54 Arg2:T56	
R50	After Arg1:T63 Arg2:T30	
R51	Overlap Arg1:T30 Arg2:T31	
R52	Overlap Arg1:T62 Arg2:T57	
R53	Overlap Arg1:T62 Arg2:T58	
#57	AnnotatorNotes T73	C0559571; At risk; Finding
#58	AnnotatorNotes T66	C4553389; Study Control; Conceptual Entity
#59	AnnotatorNotes T75	C2732579; Completion of clinical trial; Finding
A7	Experiencer T37 Patient
A8	Experiencer T40 Patient
A9	Experiencer T41 Patient
A10	Experiencer T46 Patient
A11	Experiencer T51 Patient
A12	Experiencer T59 Other
A13	Experiencer T60 Patient
A14	Assertion T24 Hypothetical
A15	Assertion T34 Hypothetical
